- Home
- XBIO vs TOVX Comparison
XBIO vs TOVX Comparison
Compare XBIO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- TOVX
- Stock Information
- Founded
- XBIO N/A
- TOVX 2001
- Country
- XBIO United States
- TOVX United States
- Employees
- XBIO N/A
- TOVX N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- TOVX Health Care
- Exchange
- XBIO Nasdaq
- TOVX Nasdaq
- Market Cap
- XBIO 4.2M
- TOVX 3.8M
- IPO Year
- XBIO N/A
- TOVX 2006
- Fundamental
- Price
- XBIO $2.96
- TOVX $0.47
- Analyst Decision
- XBIO Hold
- TOVX Hold
- Analyst Count
- XBIO 1
- TOVX 1
- Target Price
- XBIO N/A
- TOVX N/A
- AVG Volume (30 Days)
- XBIO 6.9K
- TOVX 1.8M
- Earning Date
- XBIO 05-13-2025
- TOVX 05-14-2025
- Dividend Yield
- XBIO N/A
- TOVX N/A
- EPS Growth
- XBIO N/A
- TOVX N/A
- EPS
- XBIO N/A
- TOVX N/A
- Revenue
- XBIO $2,582,728.00
- TOVX N/A
- Revenue This Year
- XBIO $14.23
- TOVX N/A
- Revenue Next Year
- XBIO $7.14
- TOVX N/A
- P/E Ratio
- XBIO N/A
- TOVX N/A
- Revenue Growth
- XBIO 5.63
- TOVX N/A
- 52 Week Low
- XBIO $2.20
- TOVX $0.40
- 52 Week High
- XBIO $5.20
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- XBIO 48.28
- TOVX 29.91
- Support Level
- XBIO $2.85
- TOVX $0.43
- Resistance Level
- XBIO $3.22
- TOVX $0.54
- Average True Range (ATR)
- XBIO 0.14
- TOVX 0.05
- MACD
- XBIO -0.00
- TOVX 0.03
- Stochastic Oscillator
- XBIO 26.91
- TOVX 41.18
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.